Sign in

    Vinicius Strano • UBS

    Vinicius Strano's questions to Hypera SA (HYPMY) leadership

    Vinicius Strano's questions to Hypera SA (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano requested a breakdown of sell-out performance by business unit (generics, OTC, prescription) and the key drivers for achieving the 8% sell-out growth target for 2025. He also asked about the expected evolution of net debt.

    Answer

    Executive Breno Pires de Oliveira described Q1 sell-out growth as balanced, with generics slightly ahead. He cited upcoming launches for major brands like Neosaldina and a recovery in the pain killers market as key growth drivers. Executive Ramon Frutuoso Silva projected year-end net debt would be close to the prior year's level, as strong cash generation is offset by CapEx and interest payments.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to Hypera SA (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano from UBS requested a breakdown of sell-out performance across generics, OTC, and prescription drugs, and asked about the key drivers for achieving the 8% sell-out growth target for 2025. He also inquired about the expected evolution of net debt throughout the year.

    Answer

    Executive Breno Pires de Oliveira noted that Q1 sell-out growth was balanced across business units, with generics performing slightly above average. He cited important new launches, like muscular Neosaldina, as key drivers for accelerating sell-out. Executive Ramon Frutuoso Silva projected that year-end net debt would be close to the previous year's level, as strong cash generation is offset by significant investments and interest payments.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to Hypera SA (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano asked for a breakdown of sell-out performance across generics, OTC, and prescription medications, the key drivers for accelerating sell-out to the expected 8% level in 2025, and the anticipated evolution of net debt throughout the year.

    Answer

    Breno Pires de Oliveira, an executive, described sell-out growth as balanced, with generics slightly above and skincare slightly below the 6% average. He cited new launches, like muscular Neosaldina, as key drivers for future acceleration. Ramon Frutuoso Silva, an executive, projected that year-end net debt would be close to the previous year's level, as higher cash generation is offset by CapEx and interest payments.

    Ask Fintool Equity Research AI